Therapeutic Controversies: Optimizing Anemia Management in Hospitalized Patients with End-Stage Renal Disease

2009 ◽  
Vol 43 (2) ◽  
pp. 276-282 ◽  
Author(s):  
Michael Heung ◽  
Bruce A Mueller ◽  
Jonathan H Segal
Keyword(s):  
Renal Disease ◽  
End Stage Renal Disease ◽  
Hospitalized Patients ◽  
Anemia Management ◽  
Stage Renal Disease ◽  
End Stage

scholarly journals Association of Pre-End-Stage Renal Disease Hemoglobin with Early Dialysis Outcomes

2018 ◽  
Vol 47 (5) ◽  
pp. 333-342 ◽  
Author(s):  
Carola-Ellen Kleine ◽  
Melissa Soohoo ◽  
Omesh N. Ranasinghe ◽  
Christina Park ◽  
Maria V. Marroquin ◽  
...  
Keyword(s):  
Renal Disease ◽  
Mortality Risk ◽  
End Stage Renal Disease ◽  
Negative Binomial ◽  
Negative Binomial Regression ◽  
Hospitalization Rate ◽  
Anemia Management ◽  
Stage Renal Disease ◽  
End Stage ◽  
The Impact

Background: Incident hemodialysis patients have a high mortality risk within the first months after dialysis initiation. Pre-end-stage renal disease (ESRD) factors like anemia management may impact early post-ESRD outcomes. Therefore, we evaluated the impact of pre-ESRD hemoglobin (Hgb) and pre-ESRD Hgb slope on post-ESRD mortality and hospitalization outcomes. Methods: The study included 31,472 veterans transitioning to ESRD. Using Cox and negative binomial regression models, we evaluated the association of pre-ESRD Hgb and Hgb slope with 12-month post-ESRD all-cause and cardiovascular mortality and hospitalization rates using 4 levels of hierarchical multivariable adjustment, including erythropoietin use and kidney decline in slope models. Results: The cohort was 2% female, 30% African-American, and on average 68 ± 11 years old. Compared to Hgb 10–< 11 g/dL, both low (< 10 g/dL) and high (≥12 g/dL) levels were associated with higher all-cause mortality after full adjustment (HR 1.25 [95% CI 1.15–1.35] and 1.09 [95% CI 1.02–1.18], respectively). Similarly, Hgb exhibited a U-shaped association with CV mortality, while only lower Hgb was associated with a higher hospitalization rate. Neither an annual pre-ESRD decline in Hgb nor increase was associated with higher post-ESRD mortality risk after adjustment for kidney decline. However, we observed a modest J-shaped association between pre-ESRD Hgb slope and post-ESRD hospitalization rate. Conclusions: Lower and higher pre-ESRD Hgb levels are associated with a higher risk of early post-ESRD mortality, while there was no association between the pre-ESRD slope and mortality. An increase in pre-ESRD Hgb slope was associated with higher risk of post-ESRD hospitalization. Additional studies aimed at anemia management prior to ESRD transition are warranted.

Impact of nocturnal home hemodialysis on anemia management in patients with end-stage renal disease

2005 ◽  
Vol 63 (03) ◽  
pp. 202-208 ◽  
Author(s):  
D.I. Schwartz ◽  
A. Pierratos ◽  
R.M.A. Richardson ◽  
S.S.A. Fenton ◽  
C.T. Chan
Keyword(s):  
Renal Disease ◽  
End Stage Renal Disease ◽  
Home Hemodialysis ◽  
Anemia Management ◽  
Stage Renal Disease ◽  
End Stage

A Multicenter Analysis of Factors Associated With Apixaban-Related Bleeding in Hospitalized Patients With End-Stage Renal Disease on Hemodialysis

2017 ◽  
Vol 51 (11) ◽  
pp. 954-960 ◽  
Author(s):  
Taylor D. Steuber ◽  
Dane L. Shiltz ◽  
Alex C. Cairns ◽  
Qian Ding ◽  
Katie J. Binger ◽  
...  
Keyword(s):  
Logistic Regression ◽  
Renal Disease ◽  
End Stage Renal Disease ◽  
Odds Ratio ◽  
The United States ◽  
Hospitalized Patients ◽  
Bleeding Events ◽  
Factors Associated ◽  
Stage Renal Disease ◽  
End Stage

Background: In 2014, the United States Food and Drug Administration approved a labeling change for apixaban to include recommendations for patients with severe renal impairment and patients with end-stage renal disease (ESRD) on hemodialysis (HD), though these recommendations are largely based on pharmacokinetic and pharmacodynamic data. Objective: Identify variables associated with bleeding events in hospitalized patients with ESRD on HD receiving apixaban. Methods: This retrospective, multicenter cohort study evaluated hospitalized patients with ESRD on HD receiving apixaban from January 1, 2013, through March 31, 2016. Correlational analysis and logistic regression were completed to identify factors associated with bleeding. Results: A total of 114 adults were included in the analysis. The median length of stay (LOS) was 6.2 (interquartile range = 3.8-11.9) days and bleeding events occurred in a total of 17 patients (15%). A weak correlation was identified for higher cumulative apixaban exposure, increased number of HD sessions while receiving apixaban, and increased hospital LOS ( P < 0.05; correlation coefficient < 0.40). When controlling for confounders, logistic regression revealed that composite bleeding events were independently increased by continuation of outpatient apixaban (odds ratio = 13.07; 95% CI = 1.54-110.54; P = 0.018), increased total daily dose of apixaban (odds ratio = 1.72; 95% CI = 1.20 to 2.48; P = 0.003), and total HD sessions while receiving apixaban (odds ratio = 2.04; 95% CI = 1.06-3.92; P = 0.033). Conclusion: The association between these factors and increased bleeding should prompt concern for long-term anticoagulation with apixaban in patients with ESRD receiving chronic HD.

scholarly journals Impact of a Pharmacist-Implemented Anemia Management in Outpatients with End-Stage Renal Disease in Japan

2004 ◽  
Vol 27 (11) ◽  
pp. 1831-1833 ◽  
Author(s):  
Takeshi Kimura ◽  
Mamiko Arai ◽  
Hiroya Masuda ◽  
Atsufumi Kawabata
Keyword(s):  
Renal Disease ◽  
End Stage Renal Disease ◽  
Anemia Management ◽  
Stage Renal Disease ◽  
End Stage

159: Administration of Ergocalciferol: Effect on Anemia Management in End Stage Renal Disease

2010 ◽  
Vol 55 (4) ◽  
pp. B71
Author(s):  
Derek Larson ◽  
Junine DeGraf ◽  
Hongyan Du ◽  
Stacey Kirshenbaum ◽  
Stuart M. Sprague ◽  
...  
Keyword(s):  
Renal Disease ◽  
End Stage Renal Disease ◽  
Anemia Management ◽  
Stage Renal Disease ◽  
End Stage

Mo1292 – End- Stage Renal Disease is Associated with Worse Outcomes in Hospitalized Patients with Peptic Ulcer Bleeding. A 5 Year of National Estimate

2019 ◽  
Vol 156 (6) ◽  
pp. S-749
Author(s):  
Navroop Nagra ◽  
Prakashkumar M. Maiyani ◽  
Anisa Chowdhary ◽  
Spirina Anastasiia ◽  
Pooja Verma ◽  
...  
Keyword(s):  
Peptic Ulcer ◽  
Renal Disease ◽  
End Stage Renal Disease ◽  
Hospitalized Patients ◽  
Ulcer Bleeding ◽  
Peptic Ulcer Bleeding ◽  
Stage Renal Disease ◽  
End Stage
Sign in / Sign up

Export Citation Format

Share Document